IN2014CN02806A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN02806A IN2014CN02806A IN2806CHN2014A IN2014CN02806A IN 2014CN02806 A IN2014CN02806 A IN 2014CN02806A IN 2806CHN2014 A IN2806CHN2014 A IN 2806CHN2014A IN 2014CN02806 A IN2014CN02806 A IN 2014CN02806A
- Authority
- IN
- India
- Prior art keywords
- compounds
- medicaments
- variables
- inhibitors
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
The present invention provides compounds of Formula (I): or stereoisomers pharmaceutically acceptable salts thereof wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161547305P | 2011-10-14 | 2011-10-14 | |
PCT/US2012/059859 WO2013055984A1 (en) | 2011-10-14 | 2012-10-12 | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CN02806A true IN2014CN02806A (en) | 2015-07-03 |
Family
ID=47080862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2806CHN2014 IN2014CN02806A (en) | 2011-10-14 | 2012-10-12 |
Country Status (7)
Country | Link |
---|---|
US (5) | US9108951B2 (en) |
EP (2) | EP2899183B1 (en) |
JP (1) | JP6033317B2 (en) |
CN (1) | CN103987697B (en) |
ES (2) | ES2699226T3 (en) |
IN (1) | IN2014CN02806A (en) |
WO (1) | WO2013055984A1 (en) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI577665B (en) | 2010-02-11 | 2017-04-11 | 必治妥美雅史谷比公司 | Macrocycles as factor xia inhibitors |
TW201311689A (en) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | Novel macrocycles as factor XIa inhibitors |
TW201319068A (en) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | Cyclic P1 linkers as factor XIa inhibitors |
PL2766346T3 (en) | 2011-10-14 | 2017-09-29 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
ES2699226T3 (en) | 2011-10-14 | 2019-02-08 | Bristol Myers Squibb Co | Substituted tetrahydroisoquinoline compounds as inhibitors of factor XIa |
CN103987696B (en) | 2011-10-14 | 2016-12-21 | 百时美施贵宝公司 | Substituted tetrahydro isoquinoline compound as factor XI, plasma thromboplastin antecedent A inhibitor |
CN108250199B (en) | 2012-08-03 | 2021-07-16 | 百时美施贵宝公司 | Dihydropyridone P1 as factor XIA inhibitor |
UY34959A (en) | 2012-08-03 | 2014-01-31 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | DIHYDROPIRIDONE P1 AS INHIBITORS OF THE XIA FACTOR |
SI2906551T1 (en) | 2012-10-12 | 2018-05-31 | Bristol-Myers Squibb Company | Crystalline forms of a factor xia inhibitor |
WO2014059214A1 (en) * | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
US9315519B2 (en) | 2012-10-12 | 2016-04-19 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors |
WO2014142255A1 (en) | 2013-03-14 | 2014-09-18 | 武田薬品工業株式会社 | Heterocyclic compound |
EP2978751B1 (en) | 2013-03-25 | 2018-12-05 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors |
JP6427491B2 (en) | 2013-07-03 | 2018-11-21 | 武田薬品工業株式会社 | Heterocyclic compounds |
JP6411342B2 (en) | 2013-07-03 | 2018-10-24 | 武田薬品工業株式会社 | Amide compounds |
WO2015047973A1 (en) * | 2013-09-27 | 2015-04-02 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
US20160257668A1 (en) | 2013-10-07 | 2016-09-08 | Merck Sharp & Dohme Corp. | Factor XIa Inhibitors |
HUE040226T2 (en) | 2014-01-31 | 2019-02-28 | Bristol Myers Squibb Co | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors |
NO2760821T3 (en) | 2014-01-31 | 2018-03-10 | ||
US9676723B2 (en) | 2014-02-11 | 2017-06-13 | Merck Sharp & Dohme Corp | Factor XIa inhibitors |
US9944643B2 (en) | 2014-02-11 | 2018-04-17 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
EP3134408B1 (en) * | 2014-04-22 | 2020-08-12 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
US9693998B2 (en) | 2014-05-16 | 2017-07-04 | Cumberland Pharmaceuticals, Inc. | Compositions and methods of treating cardiac fibrosis with ifetroban |
PE20170267A1 (en) * | 2014-07-01 | 2017-04-12 | Takeda Pharmaceuticals Co | HETEROCYCLIC COMPOUNDS AND THEIR USE AS T-RANGE INHIBITORS OF THE RETINOID-RELATED ORPHAN RECEPTOR (ROR) |
EP3180317B1 (en) | 2014-07-28 | 2021-04-14 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
MY187540A (en) | 2014-08-01 | 2021-09-28 | Nuevolution As | Compounds active towards bromodomains |
CN105461688B (en) * | 2014-08-26 | 2017-12-29 | 上海医药工业研究院 | Benzimidazole compound K synthetic method |
WO2016036893A1 (en) | 2014-09-04 | 2016-03-10 | Bristol-Myers Squibb Company | Diamide macrocycles that are fxia inhibitors |
US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
NZ730247A (en) * | 2014-10-01 | 2022-11-25 | Medimmune Ltd | Antibodies to ticagrelor and methods of use |
EP3310777B1 (en) | 2015-06-19 | 2019-10-09 | Bristol-Myers Squibb Company | Diamide macrocycles as factor xia inhibitors |
US20170000771A1 (en) | 2015-06-30 | 2017-01-05 | Cumberland Pharmaceuticals, Inc. | Thromboxane Receptor Antagonists in AERD/Asthma |
EP3319959B1 (en) | 2015-07-06 | 2021-09-01 | Alkermes, Inc. | Hetero-halo inhibitors of histone deacetylase |
EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
ES2937156T3 (en) | 2015-07-29 | 2023-03-24 | Bristol Myers Squibb Co | Macrocyclic factor XIa inhibitors bearing a non-aromatic P2' group |
ES2803659T3 (en) | 2015-07-29 | 2021-01-28 | Bristol Myers Squibb Co | Macrocyclic factor xia inhibitors containing p2 alkyl or cycloalkyl moieties |
EP3371162B1 (en) | 2015-10-29 | 2022-01-26 | Merck Sharp & Dohme Corp. | Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use |
AU2016344476B2 (en) | 2015-10-29 | 2020-08-13 | Merck Sharp & Dohme Llc | Factor XIa inhibitors |
EP3401686B1 (en) * | 2016-01-07 | 2022-10-05 | Fujimori Kogyo Co., Ltd. | Method for analyzing blood characteristics |
CN107540659A (en) * | 2016-06-29 | 2018-01-05 | 四川科伦博泰生物医药股份有限公司 | Tetrahydroisoquinolicompounds compounds, its preparation method, medical composition and its use |
US10143681B2 (en) | 2016-08-22 | 2018-12-04 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
WO2018132531A1 (en) | 2017-01-11 | 2018-07-19 | Rodin Therapeutics, Inc. | Bicyclic inhibitors of histone deacetylase |
SG11202000970WA (en) | 2017-08-07 | 2020-02-27 | Rodin Therapeutics Inc | Bicyclic inhibitors of histone deacetylase |
CN109721539B (en) * | 2017-10-27 | 2021-07-09 | 天津药物研究院有限公司 | Pyrazole amide derivative and preparation method and application thereof |
CN109867660A (en) * | 2017-12-01 | 2019-06-11 | 四川科伦博泰生物医药股份有限公司 | Tetrahydroisoquinoline amide compound and its medicinal usage containing quaternary ammonium ion |
JP7458984B2 (en) | 2018-03-28 | 2024-04-01 | 四川科倫博泰生物医薬股▲フン▼有限公司 | Tetrahydroisoquinoline derivatives, their production methods and uses |
WO2020065614A1 (en) * | 2018-09-28 | 2020-04-02 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
CN112996785A (en) * | 2018-10-22 | 2021-06-18 | 希四克斯探索有限公司 | Therapeutic compounds |
WO2020094156A1 (en) * | 2018-11-11 | 2020-05-14 | 上海海雁医药科技有限公司 | Diheterocycle-substituted pyridine-2(1h)-ketone derivative, preparation method therefore and pharmaceutical use thereof |
CN116133660A (en) * | 2020-07-22 | 2023-05-16 | 詹森药业有限公司 | Compounds useful as factor XIa inhibitors |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1525186A (en) | 1967-03-29 | 1968-05-17 | Roussel Uclaf | New penicillins and method of preparation |
DE3065190D1 (en) | 1979-11-05 | 1983-11-10 | Beecham Group Plc | Enzyme derivatives, and their preparation |
US4843062A (en) | 1987-12-23 | 1989-06-27 | American Home Products Corporation | N-acyl-N-napthoylglycines as aldose reductase inhibitors |
DE4034829A1 (en) | 1990-11-02 | 1992-05-07 | Merck Patent Gmbh | CYCLOPEPTIDE |
JP3190431B2 (en) | 1991-07-01 | 2001-07-23 | 三菱化学株式会社 | Ketone derivatives |
GB9206757D0 (en) | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
US5624936A (en) | 1995-03-29 | 1997-04-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1996034010A2 (en) | 1995-03-29 | 1996-10-31 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5869682A (en) | 1996-04-03 | 1999-02-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
JP2000507597A (en) | 1996-04-03 | 2000-06-20 | メルク エンド カンパニー インコーポレーテッド | Farnesyl protein transferase inhibitor |
PE121699A1 (en) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | BICYCLE HETERO CYCLES DISSTITUTED AS INHIBITORS OF THROMBIN |
ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
PT1064298E (en) | 1998-03-19 | 2009-01-02 | Vertex Pharma | Inhibitors of caspases |
AU763839B2 (en) | 1998-05-26 | 2003-07-31 | Warner-Lambert Company | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation |
US6307049B1 (en) | 1998-09-30 | 2001-10-23 | The Procter & Gamble Co. | Heterocyclic 2-substituted ketoamides |
KR20010101355A (en) | 1999-01-02 | 2001-11-14 | 로버트 흐라이탁, 미쉘 베스트 | Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them(inhibition of factor XA activity) |
EP1016663A1 (en) | 1999-01-02 | 2000-07-05 | Aventis Pharma Deutschland GmbH | Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity) |
HUP0203167A3 (en) | 1999-04-09 | 2003-09-29 | Basf Ag | Peptidic substances, their preparations and their use as complement protease inhibitors |
WO2000076970A2 (en) | 1999-06-14 | 2000-12-21 | Eli Lilly And Company | Serine protease inhibitors |
DE19962924A1 (en) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituted oxazolidinones and their use |
EP1125925A1 (en) | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Amine derivatives for the treatment of apoptosis |
DE60115227T2 (en) * | 2000-05-11 | 2006-08-24 | Bristol-Myers Squibb Co. | TETRAHYDROISOCHINOLINE ANALOGUE AS GROWTH HORMONE SECRETAGOGA |
SV2003000617A (en) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M |
AR035216A1 (en) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | MANDELIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE DERIVATIVES, USE OF THESE DERIVATIVES FOR THE MANUFACTURE OF MEDICINES, TREATMENT METHODS, PROCESSES FOR THE PREPARATION OF THESE DERIVATIVES, AND INTERMEDIARY COMPOUNDS |
US6770647B2 (en) | 2001-08-17 | 2004-08-03 | Bristol-Myers Squibb Pharma Company | Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
CH1427415H1 (en) | 2001-09-21 | 2023-12-21 | Bristol Myers Squibb Holdings Ireland | LACTAM-CONTAINING COMPOUNDS AND THEIR DERIVATIVES AS FACTOR XA INHIBITORS |
WO2003041641A2 (en) * | 2001-11-09 | 2003-05-22 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity |
GB0206033D0 (en) | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
US20040180855A1 (en) | 2003-02-19 | 2004-09-16 | Schumacher William A. | Methods of treating thrombosis with reduced risk of increased bleeding times |
US7138412B2 (en) | 2003-03-11 | 2006-11-21 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives useful as serine protease inhibitors |
US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
JP2007501844A (en) * | 2003-08-08 | 2007-02-01 | トランス テック ファーマ,インコーポレイテッド | Aryl and heteroaryl compounds, compositions and methods of use |
US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
WO2006017295A2 (en) | 2004-07-12 | 2006-02-16 | Idun Pharmaceuticals, Inc. | Tetrapeptide analogs |
WO2006076575A2 (en) | 2005-01-13 | 2006-07-20 | Bristol-Myers Squibb Company | Substituted biaryl compounds as factor xia inhibitors |
US20060183771A1 (en) | 2005-02-17 | 2006-08-17 | Seiffert Dietmar A | Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors |
CA2612279C (en) | 2005-06-17 | 2014-04-15 | Basf Aktiengesellschaft | Process of producing bleach boosters |
CN101304989A (en) | 2005-11-11 | 2008-11-12 | 弗·哈夫曼-拉罗切有限公司 | Carbocyclic fused cyclic amines as inhibitors of the coagulation factor XA |
US8466295B2 (en) | 2005-12-14 | 2013-06-18 | Bristol-Myers Squibb Company | Thiophene derivatives as factor XIa inhibitors |
KR20080087817A (en) | 2005-12-14 | 2008-10-01 | 브리스톨-마이어스 스큅 컴퍼니 | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
EP1966141A1 (en) | 2005-12-14 | 2008-09-10 | Brystol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
AU2007288253B2 (en) | 2006-08-23 | 2013-05-02 | Xenon Pharmaceuticals Inc. | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators |
EP2102189B1 (en) | 2006-12-15 | 2015-07-29 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
AR067329A1 (en) | 2007-06-13 | 2009-10-07 | Bristol Myers Squibb Co | ANALOGS DIPEPTIDOS AS INHIBITORS OF THE COAGULATION FACTOR |
AR067336A1 (en) | 2007-06-28 | 2009-10-07 | Novartis Ag | CALICREIN MODULATORS 7 |
CN102026996B (en) | 2008-03-13 | 2015-01-07 | 百时美施贵宝公司 | Pyridazine derivatives as factor XIA inhibitors |
WO2010151317A1 (en) | 2009-06-22 | 2010-12-29 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
WO2011002520A2 (en) | 2009-07-02 | 2011-01-06 | Angion Biomedica Corp. | Small molecule inhibitors of parp activity |
EP2462123B1 (en) | 2009-08-04 | 2013-10-02 | Merck Sharp & Dohme Corp. | 4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors |
TWI577665B (en) | 2010-02-11 | 2017-04-11 | 必治妥美雅史谷比公司 | Macrocycles as factor xia inhibitors |
EP2729150B1 (en) | 2011-07-08 | 2016-09-14 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
TW201319068A (en) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | Cyclic P1 linkers as factor XIa inhibitors |
TW201311689A (en) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | Novel macrocycles as factor XIa inhibitors |
ES2699226T3 (en) | 2011-10-14 | 2019-02-08 | Bristol Myers Squibb Co | Substituted tetrahydroisoquinoline compounds as inhibitors of factor XIa |
CN103987696B (en) | 2011-10-14 | 2016-12-21 | 百时美施贵宝公司 | Substituted tetrahydro isoquinoline compound as factor XI, plasma thromboplastin antecedent A inhibitor |
PL2766346T3 (en) | 2011-10-14 | 2017-09-29 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
EP3290413B9 (en) | 2011-12-21 | 2020-04-29 | ONO Pharmaceutical Co., Ltd. | Pyridinone and pyrimidinone derivatives as factor xia inhibitors |
EP2807156A1 (en) | 2012-01-27 | 2014-12-03 | Novartis AG | Aminopyridine derivatives as plasma kallikrein inhibitors |
WO2013111108A1 (en) | 2012-01-27 | 2013-08-01 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
JP2015083542A (en) | 2012-02-08 | 2015-04-30 | 大日本住友製薬株式会社 | Three substituted proline derivative |
LT2847228T (en) | 2012-05-10 | 2018-11-12 | Bayer Pharma Aktiengesellschaft | ANTIBODIES CAPABLE OF BINDING TO THE COAGULATION FACTOR XI AND/OR ITS ACTIVATED FORM FACTOR XIa AND USES THEREOF |
TW201416362A (en) | 2012-07-19 | 2014-05-01 | Dainippon Sumitomo Pharma Co | 1-(cycloalkylcarbonyl)proline derivatives |
CN108250199B (en) | 2012-08-03 | 2021-07-16 | 百时美施贵宝公司 | Dihydropyridone P1 as factor XIA inhibitor |
UY34959A (en) | 2012-08-03 | 2014-01-31 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | DIHYDROPIRIDONE P1 AS INHIBITORS OF THE XIA FACTOR |
-
2012
- 2012-10-12 ES ES14195397T patent/ES2699226T3/en active Active
- 2012-10-12 ES ES12778912.1T patent/ES2572908T3/en active Active
- 2012-10-12 US US14/350,417 patent/US9108951B2/en active Active
- 2012-10-12 IN IN2806CHN2014 patent/IN2014CN02806A/en unknown
- 2012-10-12 EP EP14195397.6A patent/EP2899183B1/en active Active
- 2012-10-12 EP EP12778912.1A patent/EP2766345B1/en active Active
- 2012-10-12 WO PCT/US2012/059859 patent/WO2013055984A1/en active Application Filing
- 2012-10-12 JP JP2014535894A patent/JP6033317B2/en active Active
- 2012-10-12 CN CN201280061670.3A patent/CN103987697B/en active Active
-
2015
- 2015-07-15 US US14/799,681 patent/US9394276B2/en active Active
-
2016
- 2016-06-15 US US15/183,051 patent/US9725435B2/en active Active
-
2017
- 2017-07-07 US US15/643,891 patent/US10000466B2/en active Active
-
2018
- 2018-05-17 US US15/982,038 patent/US10906886B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20180265494A1 (en) | 2018-09-20 |
US9394276B2 (en) | 2016-07-19 |
WO2013055984A1 (en) | 2013-04-18 |
US20160289209A1 (en) | 2016-10-06 |
JP6033317B2 (en) | 2016-11-30 |
CN103987697A (en) | 2014-08-13 |
ES2572908T3 (en) | 2016-06-03 |
CN103987697B (en) | 2017-04-26 |
US9108951B2 (en) | 2015-08-18 |
EP2899183B1 (en) | 2018-09-19 |
US10906886B2 (en) | 2021-02-02 |
EP2899183A1 (en) | 2015-07-29 |
ES2699226T3 (en) | 2019-02-08 |
EP2766345A1 (en) | 2014-08-20 |
US20170305880A1 (en) | 2017-10-26 |
US10000466B2 (en) | 2018-06-19 |
US9725435B2 (en) | 2017-08-08 |
US20140275061A1 (en) | 2014-09-18 |
EP2766345B1 (en) | 2016-03-16 |
US20150315200A1 (en) | 2015-11-05 |
JP2014528479A (en) | 2014-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CN02806A (en) | ||
IN2014CN02805A (en) | ||
TN2014000155A1 (en) | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors | |
MX2015000892A (en) | Dihydropyridone p1 as factor xia inhibitors. | |
MX2015000919A (en) | Dihydropyridone p1 as factor xia inhibitors. | |
PH12016500072B1 (en) | Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof | |
UA108442C2 (en) | Indazol | |
EP4219465A3 (en) | Prmt5 inhibitors and uses thereof | |
PH12015500064B1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
IN2015DN01156A (en) | ||
IN2014MN02658A (en) | ||
AU2012214029A8 (en) | Rorgammat inhibitors | |
MY177344A (en) | Compounds and their methods of use | |
MY162936A (en) | Macrocycles as factor xia inhibitors | |
UA111382C2 (en) | Protein kinase inhibitors | |
MX345763B (en) | Novel macrocycles as factor xia inhibitors. | |
IN2015DN00598A (en) | ||
MX2016000675A (en) | Aminomethyl-biaryl derivatives as complement factor d inhibitors and uses thereof. | |
IN2015DN00185A (en) | ||
IN2014CN03803A (en) | ||
JO3115B1 (en) | Pyridazinone Compounds and Their Use as DAAO Inhibitors | |
MX2014014253A (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors. | |
IN2014DN06869A (en) | ||
GB201209587D0 (en) | Therapeutic compounds | |
MX2013008340A (en) | Novel 4-amino-n-hydroxy-benzamides as hdac inhibitors for the treatment of cancer. |